alogliptin
Trade name: nesina
Approved
Jan 25, 2013
Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, discovered by Takeda Pharmaceutical Company's wholly owned subsidiary, Takeda San Diego, Inc. (former Syrrx) which was acquired by Takeda in 2005. Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone. — NCATS
Clinical trial activity
61 trials · 17 clinical orgs · 4 marketing orgs
Earliest trial started Mar 1, 2005 (NCT00755846)
Timeline
2000s
2010s
- Jan 25, 2013
Takeda — Earliest FDA Approval
- Jan 25, 2013
Takeda — NDA Organization
- Dec 19, 2018
Torrent Pharmaceuticals Limited — Marketing Organization
- Jan 29, 2019
MSN Laboratories — Marketing Organization
- Dec 23, 2019
Indoco Remedies — Marketing Organization
Indications
Approved for
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
DPP4 inhibitor
Combination products
kazano
with metformin
oseni
with pioglitazone
Approval history
- approvedJan 25, 2013
Chemistry & pharmacology
SMILES
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O- Mol. weight
- 339.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL376359 ↗
- WikipediaAlogliptin ↗
- NCATSJHC049LO86 ↗
- ChEMBLCHEMBL227529 ↗
Also known as
- 2-((6-((3r)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)methyl) benzonitrile
- alogliptin
- alogliptin
- alogliptin
- alogliptin
- alogliptin
- alogliptin
- alogliptin
- alogliptin
- alogliptin
- alogliptin
- alogliptina
- alogliptina
- alogliptin benzoate
- alogliptin benzoate
- alogliptin benzoate
- alogliptin benzoate
- alogliptin benzoate
- alogliptin benzoate / metformin hydrochloride
- alogliptine
- alogliptine
- alogliptin / metformin
- alogliptin / pioglitazone
- alogliptinum
- alogliptinum
- nesina
- nesina
- nesina
- nesina
- nesina
- syr322
- syr 322
- syr-322
- syr-322
- syr-322
- syr-322
- vipdomet
- vipidia
- vipidia
- vipidia
- vipidia
- vipidia
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07093476 | Phase 3 | Jul 18, 2025 | Celltrion |
| NCT05364164 | Phase 1 | Jul 9, 2022 | Celltrion |
| NCT05363592 | Phase 1 | Jun 25, 2022 | Celltrion |
| NCT05363384 | Phase 1 | Jun 11, 2022 | Celltrion |
| NCT06883656 | Phase 1 | Mar 15, 2022 | Shenzhen Salubris Pharmaceuticals Co., Ltd. |
| NCT05318326 | Phase 3 | Jan 1, 2022 | Chengdu Easton Biopharmaceuticals Co,Ltd, Peking University |
| NCT04392557 | Phase 4 | Jul 31, 2020 | Magna Graecia University |
| NCT05801627 | Phase 3 | May 6, 2020 | Peking University, Shenzhen Salubris Pharmaceuticals Co., Ltd. |
| NCT03950505 | Phase 4 | Jun 30, 2019 | Yonsei University |
| NCT05782192 | Phase 3 | Jun 13, 2019 | Shenzhen Salubris Pharmaceuticals Co., Ltd., Sun Yat-Sen University |
| NCT03794336 | Phase 4 | Apr 30, 2019 | Sanofi |
| NCT03499704 | Phase 4 | Jan 15, 2019 | Takeda |
| NCT03501277 | Phase 1 | May 25, 2018 | Takeda |
| NCT03231709 | Phase 4 | Aug 16, 2017 | Takeda |
| NCT03042325 | Phase 4 | Jul 30, 2017 | Takeda |
| NCT03014479 | Phase 4 | Jan 12, 2017 | Takeda |
| NCT02856113 | Phase 3 | Nov 28, 2016 | Takeda |
| NCT02823808 | Phase 4 | Aug 1, 2016 | Kyung Hee University, Takeda |
| NCT02771093 | Phase 4 | Jun 1, 2016 | Takeda |
| NCT02763007 | Phase 4 | May 1, 2016 | Catholic University of Korea, Takeda |
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 45 | 42 | 4 | 2005 |
| Kawasaki Medical University | Academic/Hospital | 9 | 0 | 2 | 2007 |
| Celltrion | For profit | 4 | 4 | 2 | 2022 |
| Shenzhen Salubris Pharmaceuticals Co., Ltd. | For profit | 3 | 3 | 2 | 2019 |
| Catholic University of Korea | Academic/Hospital | 2 | 2 | 1 | 2014 |
| Peking University | Academic/Hospital | 2 | 0 | 1 | 2020 |
| Aichi Gakuin University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2012 |
| Chengdu Easton Biopharmaceuticals Co,Ltd | For profit | 1 | 1 | 1 | 2022 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Kyung Hee University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Magna Graecia University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Sanofi | For profit | 1 | 1 | 1 | 2019 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Ljubljana | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2019 |
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Indoco Remedies | For profit | MKTG | Dec 23, 2019 |
| MSN Laboratories | For profit | MKTG | Jan 29, 2019 |
| MSN Laboratories | For profit | SYN | Nov 27, 2019 |
| Takeda | For profit | NDA | Jan 25, 2013 |
| Torrent Pharmaceuticals Limited | For profit | MKTG | Dec 19, 2018 |